Lamivudine/nevirapine/zidovudine
Combination of | |
---|---|
Lamivudine | nucleoside reverse transcriptase inhibitor |
Nevirapine | non-nucleoside reverse transcriptase inhibitor |
Zidovudine | nucleoside reverse transcriptase inhibitor |
Clinical data | |
Trade names | Duovir-N, Zidovex-LN, others[1] |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a
The medication is generally well tolerated.liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[2]
It is on the World Health Organization's List of Essential Medicines.[3] The combination is not commercially available in the United States as of 2018.[4]
See also
References
- ^ a b c d e "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
- ^ ISBN 9789241547659.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.